Quantcast

Industry news that matters to you.  Learn more

QIAGEN Partners With World’s Largest Sequencing Provider

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) recently today that it has expanded its relationship with BGI, the world’s largest genomics organization, to provide QIAGEN’s Ingenuity® Variant Analysis™ in integrated bioinformatics for all customers of BGI’s sequencing services.

Genome Canada Unveils Canada’s New Genomics Innovation Network

Genome Canada is pleased to announce a $15.5 million investment in Canada’s new Genomics Innovation Network. The Network is comprised of ten “Nodes,” each receiving core operational funding from Genome Canada, with matching funds from various public and private sector partners.

SCIEX Announces OneOmics Collaborators

SCIEX, a global leader in life science analytical technologies, recently announced collaborators in the OneOmics™ project, an exclusive partnership between Illumina and SCIEX that integrates SWATH™ Acquisition based next-generation proteomics (NGP) and next-generation sequencing (NGS) data on the BaseSpace® cloud computing environment. Advaita Bioinformatics, The Institute for Systems Biology (ISB) and researchers at Yale University have each developed cloud-based applications and libraries that utilize SWATH Proteomics data in novel ways allowing researchers to analyze and compare proteomics and genomics data. This effort furthers the OneOmics project’s goal of eliminating the informatics barriers that exist between different Omics disciplines.

DNAnexus Powers Intermountain Cancer Genomics to Deliver Precision Medicine to Cancer Patients

DNAnexus Inc., a pioneer in cloud-based genome informatics and data management, recently announced that Intermountain Cancer Genomics is now using DNAnexus as the underlying bioinformatics platform for the center’s personalized treatment options for cancer patients.

CirQuest Labs Expands Predictive Laboratory Analytic Capabilities

CirQuest Labs recently announced it is expanding predictive laboratory analytic capabilities to meet the growing needs of clients seeking to determine how persons’ genetic differences may affect their response to drug therapy. The breakthrough analytical technology and companion bioinformatics makes it possible to determine the effects of genetic variation on drug efficiency, drug metabolism and drug toxicity early in the drug development process.